IL123902A - PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION CONTAINING ACYL-CoA CHOLESTEROL O-ACYLTRANSFERASE (ACAT) INHIBITOR AND AN HMG-CoA REDUCTASE INHIBITOR - Google Patents

PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION CONTAINING ACYL-CoA CHOLESTEROL O-ACYLTRANSFERASE (ACAT) INHIBITOR AND AN HMG-CoA REDUCTASE INHIBITOR

Info

Publication number: IL123902A
Authority: IL; Israel
Prior art keywords: inhibitor; coa; acat; acyltransferase; hmg
Prior art date: 1995-11-02

Application number

IL12390296A

Other languages

English (en)

Other versions

IL123902A0 (en

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-02

Filing date

1996-10-02

Publication date

2003-01-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21719566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL123902(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-10-02 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

1998-10-30 Publication of IL123902A0 publication Critical patent/IL123902A0/xx

2003-01-12 Publication of IL123902A publication Critical patent/IL123902A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL12390296A 1995-11-02 1996-10-02 PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION CONTAINING ACYL-CoA CHOLESTEROL O-ACYLTRANSFERASE (ACAT) INHIBITOR AND AN HMG-CoA REDUCTASE INHIBITOR IL123902A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US615595P	1995-11-02	1995-11-02
PCT/US1996/015854 WO1997016184A1 (en)	1995-11-02	1996-10-02	Method and pharmaceutical composition for regulating lipid concentration

Publications (2)

Publication Number	Publication Date
IL123902A0 IL123902A0 (en)	1998-10-30
IL123902A true IL123902A (en)	2003-01-12

Family

ID=21719566

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12390296A IL123902A (en)	1995-11-02	1996-10-02	PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION CONTAINING ACYL-CoA CHOLESTEROL O-ACYLTRANSFERASE (ACAT) INHIBITOR AND AN HMG-CoA REDUCTASE INHIBITOR

Country Status (27)

Country	Link
US (3)	US6124309A (xx)
EP (1)	EP0858336B1 (xx)
JP (1)	JPH11515025A (xx)
KR (2)	KR100449604B1 (xx)
CN (2)	CN1679953A (xx)
AR (1)	AR004527A1 (xx)
AT (1)	ATE348607T1 (xx)
AU (1)	AU720853B2 (xx)
BG (1)	BG64018B1 (xx)
BR (1)	BR9611410A (xx)
CZ (1)	CZ127198A3 (xx)
DE (1)	DE69636783T2 (xx)
EA (1)	EA000514B1 (xx)
ES (1)	ES2279526T3 (xx)
GE (1)	GEP20001898B (xx)
HK (1)	HK1016509A1 (xx)
HU (1)	HUP9901865A3 (xx)
IL (1)	IL123902A (xx)
IS (1)	IS4720A (xx)
NO (1)	NO981961L (xx)
NZ (2)	NZ512484A (xx)
PL (1)	PL186714B1 (xx)
RO (1)	RO120816B1 (xx)
SK (1)	SK284142B6 (xx)
UA (1)	UA46069C2 (xx)
WO (1)	WO1997016184A1 (xx)
ZA (1)	ZA969187B (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6268392B1 (en) *	1994-09-13	2001-07-31	G. D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
BR9611410A (pt) *	1995-11-02	1999-01-05	Warner Lambert Co	Método e composição farmacêutica para regular a concentração de lipídios
GT199800127A (es) *	1997-08-29	2000-02-01		Combinaciones terapeuticas.
EP1514543A1 (en) *	1997-08-29	2005-03-16	Pfizer Inc.	Combination therapy comprising atorvastatin and an antihypertensive agent
GT199800126A (es) *	1997-08-29	2000-01-29		Terapia de combinacion.
JP2002506818A (ja) *	1998-03-17	2002-03-05	ワーナー−ランバート・カンパニー	スタチン−マトリックスメタロプロテイナーゼ阻害剤組み合わせ物
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
EP1117392B1 (en) *	1998-09-30	2004-02-25	Warner-Lambert Company Llc	Method for preventing or delaying catheter-based revascularization
CO5140104A1 (es)	1999-02-16	2002-03-22	Novartis Ag	Derivados de mevinolina y preparacion farmaceuticas que los contienen
US20010006656A1 (en) *	1999-02-17	2001-07-05	University Of Washington	Methods and compositions for inhibiting inflammation associated with pulmonary disease
WO2001022962A1 (en) *	1999-09-30	2001-04-05	Merck & Co., Inc.	Anti-hypercholesterolemic drug combination
EP1092432A1 (fr) *	1999-10-15	2001-04-18	Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.)	Composes anti-ischemiques
WO2001034127A1 (en) *	1999-11-05	2001-05-17	Warner-Lambert Company	Prevention of plaque rupture by acat inhibitors
RU2246302C2 (ru) *	2000-09-01	2005-02-20	Санкио Компани, Лимитед	Фармацевтическая композиция для профилактики и лечения нарушений липидного обмена
AU2002211667A1 (en)	2000-10-11	2002-04-22	Esperion Therapeutics, Inc.	Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US6713507B2 (en)	2000-10-11	2004-03-30	Esperion Therapeutics, Inc.	Ether compounds and compositions for cholesterol management and related uses
US20040122091A1 (en) *	2000-10-11	2004-06-24	Esperion Therapeutics, Inc.	Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US7304093B2 (en) *	2000-10-11	2007-12-04	Esperion Therapeutics, Inc.	Ketone compounds and compositions for cholesterol management and related uses
CA2425674A1 (en)	2000-10-11	2002-04-18	Jean-Louis H. Dasseux	Sulfide and disulfide compounds and compositions for cholesterol management and related uses
JP2004511453A (ja)	2000-10-11	2004-04-15	エスペリオン　セラピューティクス，インコーポレイテッド	コレステロールの制御及び関連する使用のためのケトン化合物及び組成物
CA2369967A1 (en) *	2001-02-12	2002-08-12	Joseph Anthony Cornicelli	Methods of treating nuclear factor-kappa b mediated diseases and disorders
PE20030324A1 (es) *	2001-07-31	2003-04-03	Warner Lambert Co	Composiciones farmaceuticas de amlodipina y atorvastatina
US20040192771A1 (en) *	2001-10-11	2004-09-30	Dasseux Jean-Louis Henri	Ether compounds and compositions for cholesterol management and related uses
US20040204502A1 (en) *	2001-10-11	2004-10-14	Dasseux Jean-Louis Henri	Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20050020694A1 (en) *	2001-10-11	2005-01-27	Dasseux Jean-Louis Henri	Sulfide and disulfide compounds and compositions for cholesterol management and related uses
EP1485077A4 (en) *	2002-03-12	2007-07-18	Merck & Co Inc	DRUGS COMBINATION THERAPY
AU2003221926A1 (en) *	2002-04-10	2003-10-27	Esperion Therapeutics, Inc.	Mimics of acyl coenzyme-a comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses
JP4187141B2 (ja) *	2002-04-12	2008-11-26	興和株式会社	新規なトロンボモジュリン発現促進剤
EP1597223B1 (en) *	2003-01-23	2017-02-22	Esperion Therapeutics Inc.	Hydroxyl compounds and compositions for cholesterol management and related uses
CN100438872C (zh)	2003-08-29	2008-12-03	兴和株式会社	2-[4-[2-(苯并咪唑-2-基-硫代)乙基]哌嗪-1-基]-n-[2,4-二(甲基硫代)-6-甲基-3-吡啶基]乙酰胺的制药用途
WO2005046706A1 (ja) *	2003-11-17	2005-05-26	Toyo Shinyaku Co., Ltd.	松樹皮抽出物を含む脂質代謝改善剤
AU2003304703A1 (en)	2003-12-24	2005-08-03	Esperion Therapeutics, Inc.	Ketone compounds and compositions for cholesterol management and related uses
WO2005102348A1 (en) *	2004-04-19	2005-11-03	Loma Linda University	Composition and method of decreasing renal ischemic damage
TW200605890A (en) *	2004-07-28	2006-02-16	Sankyo Co	Pharmaceutical compositions for inhibiting arteriosclerosis
MX2007005129A (es) *	2004-10-27	2007-09-11	Daiichi Sankyo Co Ltd	Compuesto de benceno que tiene 2 o mas sustituyentes.
TW200619204A (en) *	2004-12-10	2006-06-16	Kowa Co	Method for reduction, stabilization and prevention of rupture of lipid rich plaque
JP2009514851A (ja) *	2005-11-08	2009-04-09	ランバクシーラボラトリーズリミテッド	（３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
EP2018153B1 (en)	2006-04-26	2012-04-11	Rosemont Pharmaceuticals Ltd	Liquid oral compositions
US20130254787A1 (en)	2006-05-02	2013-09-26	Invidi Technologies Corporation	Method and apparatus to perform real-time audience estimation and commercial selection suitable for targeted advertising
US20070269503A1 (en) *	2006-05-16	2007-11-22	James Walter Burgess	Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
US8314080B2 (en)	2010-04-06	2012-11-20	Kuwait University	Method of treating type I diabetes
CN103274985B (zh) *	2010-12-03	2016-03-09	上海科州药物研发有限公司	一种阿托伐他汀氨基酸盐
US8586527B2 (en) *	2011-10-20	2013-11-19	Jaipal Singh	Cerivastatin to treat pulmonary disorders
CA2853285C (en)	2011-10-28	2020-05-05	Lumena Pharmaceuticals, Inc.	Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
CN103304496A (zh) *	2012-03-08	2013-09-18	南京工业大学	一种合成申嗪霉素方法
PL2812005T3 (pl)	2012-05-16	2019-01-31	Prairie Berry Europe Gmbh	Polihydroksylowane pentacykliczne kwasy triterpenowe jako inhibitory reduktazy HMG-CoA
CA2978204A1 (en)	2015-03-13	2016-09-22	Esperion Therapeutics, Inc.	Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (fr)	2015-03-16	2018-01-23	Esperion Therapeutics Inc	Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
EP3986859A1 (en)	2019-06-21	2022-04-27	Esperion Therapeutics, Inc.	Methods of making bempedoic acid and compositions of the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4739073A (en) *	1983-11-04	1988-04-19	Sandoz Pharmaceuticals Corp.	Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
CA2003478A1 (en) *	1988-12-12	1990-06-12	Leonard G. Dennick	Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
FI94339C (fi) *	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2048395A1 (en) *	1990-08-23	1992-02-24	Henry Y. Pan	Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin
ES2107548T3 (es)	1991-07-23	1997-12-01	Schering Corp	Compuestos de beta-lactama sustituidos utiles como agentes hipocolesterolemicos y procedimientos para su preparacion.
WO1994009774A1 (en) *	1992-10-26	1994-05-11	Merck & Co., Inc.	Biologically active compounds and process therefor
LT3300B (en)	1992-12-23	1995-06-26	Schering Corp	Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5491172A (en) *	1993-05-14	1996-02-13	Warner-Lambert Company	N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
IL109431A (en) *	1993-05-14	2001-01-11	Warner Lambert Co	Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
WO1995013063A1 (en) *	1993-11-09	1995-05-18	Merck & Co., Inc.	HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
BR9611410A (pt) *	1995-11-02	1999-01-05	Warner Lambert Co	Método e composição farmacêutica para regular a concentração de lipídios

1996
- 1996-10-02 BR BR9611410A patent/BR9611410A/pt not_active Application Discontinuation
- 1996-10-02 DE DE69636783T patent/DE69636783T2/de not_active Expired - Fee Related
- 1996-10-02 AU AU72539/96A patent/AU720853B2/en not_active Ceased
- 1996-10-02 HU HU9901865A patent/HUP9901865A3/hu unknown
- 1996-10-02 SK SK557-98A patent/SK284142B6/sk unknown
- 1996-10-02 RO RO98-00919A patent/RO120816B1/ro unknown
- 1996-10-02 KR KR10-1998-0703240A patent/KR100449604B1/ko not_active IP Right Cessation
- 1996-10-02 KR KR10-2004-7003107A patent/KR20040029459A/ko active Search and Examination
- 1996-10-02 GE GEAP19964269A patent/GEP20001898B/en unknown
- 1996-10-02 CN CNA2005100517235A patent/CN1679953A/zh active Pending
- 1996-10-02 US US09/051,368 patent/US6124309A/en not_active Expired - Fee Related
- 1996-10-02 EP EP96934020A patent/EP0858336B1/en not_active Revoked
- 1996-10-02 IL IL12390296A patent/IL123902A/xx not_active IP Right Cessation
- 1996-10-02 CN CN961980109A patent/CN1217656C/zh not_active Expired - Fee Related
- 1996-10-02 PL PL96326365A patent/PL186714B1/pl not_active IP Right Cessation
- 1996-10-02 CZ CZ981271A patent/CZ127198A3/cs unknown
- 1996-10-02 NZ NZ512484A patent/NZ512484A/xx unknown
- 1996-10-02 JP JP9517342A patent/JPH11515025A/ja not_active Ceased
- 1996-10-02 ES ES96934020T patent/ES2279526T3/es not_active Expired - Lifetime
- 1996-10-02 EA EA199800420A patent/EA000514B1/ru not_active IP Right Cessation
- 1996-10-02 WO PCT/US1996/015854 patent/WO1997016184A1/en not_active Application Discontinuation
- 1996-10-02 UA UA98052811A patent/UA46069C2/uk unknown
- 1996-10-02 AT AT96934020T patent/ATE348607T1/de not_active IP Right Cessation
- 1996-10-02 NZ NZ319906A patent/NZ319906A/en unknown
- 1996-10-31 ZA ZA969187A patent/ZA969187B/xx unknown
- 1996-11-01 AR ARP960105005A patent/AR004527A1/es unknown
1998
- 1998-04-17 IS IS4720A patent/IS4720A/is unknown
- 1998-04-29 BG BG102417A patent/BG64018B1/bg unknown
- 1998-04-30 NO NO981961A patent/NO981961L/no unknown
1999
- 1999-04-21 HK HK99101732A patent/HK1016509A1/xx not_active IP Right Cessation
- 1999-07-01 US US09/345,944 patent/US6093719A/en not_active Expired - Fee Related
- 1999-07-01 US US09/346,503 patent/US6143755A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CZ127198A3 (cs)	1998-12-16
DE69636783T2 (de)	2007-10-18
ZA969187B (en)	1997-05-29
US6124309A (en)	2000-09-26
US6143755A (en)	2000-11-07
AU720853B2 (en)	2000-06-15
SK284142B6 (sk)	2004-10-05
GEP20001898B (en)	2000-01-05
ATE348607T1 (de)	2007-01-15
NO981961D0 (no)	1998-04-30
PL326365A1 (en)	1998-09-14
EA199800420A1 (ru)	1998-10-29
IS4720A (is)	1998-04-17
KR19990067270A (ko)	1999-08-16
EA000514B1 (ru)	1999-10-28
HK1016509A1 (en)	1999-11-05
BG102417A (en)	1999-01-29
JPH11515025A (ja)	1999-12-21
NZ319906A (en)	2000-02-28
KR20040029459A (ko)	2004-04-06
CN1679953A (zh)	2005-10-12
US6093719A (en)	2000-07-25
AU7253996A (en)	1997-05-22
EP0858336A1 (en)	1998-08-19
PL186714B1 (pl)	2004-02-27
BR9611410A (pt)	1999-01-05
ES2279526T3 (es)	2007-08-16
HUP9901865A3 (en)	2000-06-28
SK55798A3 (en)	1999-06-11
KR100449604B1 (ko)	2004-11-16
HUP9901865A2 (hu)	1999-10-28
NZ512484A (en)	2003-02-28
CN1201389A (zh)	1998-12-09
WO1997016184A1 (en)	1997-05-09
CN1217656C (zh)	2005-09-07
AR004527A1 (es)	1998-12-16
DE69636783D1 (de)	2007-02-01
UA46069C2 (uk)	2002-05-15
EP0858336B1 (en)	2006-12-20
NO981961L (no)	1998-05-04
IL123902A0 (en)	1998-10-30
BG64018B1 (bg)	2003-10-31
RO120816B1 (ro)	2006-08-30

Publication	Publication Date	Title
IL123902A (en)	2003-01-12	PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION CONTAINING ACYL-CoA CHOLESTEROL O-ACYLTRANSFERASE (ACAT) INHIBITOR AND AN HMG-CoA REDUCTASE INHIBITOR
AU2157400A (en)	2000-07-31	Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
AU4854796A (en)	1996-07-24	System and method for electronic sale of goods
AU2457299A (en)	1999-08-02	Advertising device and method for use at point of sale
AU2455497A (en)	1997-11-12	Method and apparatus for scheduling the presentation of messages to computer users
AU5338498A (en)	1998-07-31	Breath test for detection of drug metabolism
AP2001002270A0 (en)	2001-09-30	Metalloproteinaise inhibitors pharmaceutical compositions containing them and their pharmaceeutical uses and methods and intermediates useful for their preparation
AU8924198A (en)	1999-03-29	Apparatus and method for determining three-dimensional representations of tortuous vessels
AU6311694A (en)	1994-12-08	Device for the direct measurement of low density lipoprotein cholesterol
AU1022795A (en)	1995-07-27	Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
AU8036794A (en)	1995-06-29	Method and apparatus for vaporization of liquid reactants
AU1119797A (en)	1997-06-05	Method and apparatus for dispensing small amounts of liquid material
AU4955496A (en)	1996-10-08	Method for determination of cholesterol in low-density lipoprotein or very low-density lipoprotein
IL121431A0 (en)	1998-01-04	Method and system for display of an additional dimension
PL331339A1 (en)	1999-07-05	Antihrombotic and antiarteriosclerotic pharmaceutical composition containing derivative of thiene pyridine as well as an inhibitor of hmg-coa reductase
AU2910797A (en)	1997-12-09	Pharmaceutical products containing a complex of an amide-type local anesthetic and a polyacrylate
AU6189596A (en)	1996-12-18	Horizontal tray and column for contacting gas and liquid
AU2871099A (en)	1999-09-06	Apparatus and methods for presentation of information relating to objects being addressed
AU1997197A (en)	1997-11-13	Device for in-line surface-hardening of products
AU4591289A (en)	1990-06-14	Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
AU1033697A (en)	1997-06-19	Method and device for promoting sales of goods or services
HUP9900911A3 (en)	2000-06-28	Esters and amides as pla2 inhibitors
AU7169698A (en)	1998-11-27	Musical score display and editing apparatus and system
AU9165498A (en)	1999-04-05	Method and apparatus for measuring properties of paper
AU5989098A (en)	1998-08-26	Substance and method for reduction of lipids and cholesterol

Legal Events

Date	Code	Title
2003-07-06	FF	Patent granted
2003-07-31	KB	Patent renewed
2007-07-24	MM9K	Patent not in force due to non-payment of renewal fees